28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 May
PNDORA
  Jeg har flere gange analyseret Pandora, senest den 20 april og inden da efter årsregnskabet i febr..
111
20 May
PNDORA
LCB84 Earnings yield er jo den omvendte P/E, og dermed det direkte afkast du får af den pris aktien ..
29
22 May
 
Hej IceT : Det er kloge ord, du kommer med her. Jeg trak mig tilbage, da jeg var 53 år. Min arbejdsp..
27
16 May
VWS
Mens vi venter på regnskab fra HMI-Vestas, kan vi kigge lidt på installeret offshore MW og på deres ..
21
19 May
BAVA
tak til Kranen og andre, for at smide lidt guld ud i form af info.   Men guldet kom først her:   htt..
20
20 May
PNDORA
investor1 Her er lidt indspark til din vurdering. Pandora tjener aktuelt 53 kr. pr. aktie om året. J..
19
17 May
FING-B
Hvem er bedst positioneret til det nye marked, Smartcards? IDEX arbejder på 1 pilotprojekt, mens FPC..
15
19 May
BAVA
Slap dog af bamse. 1.000 i 2017 er et temmelig vildt gæt. Og det er vel at mærke et gæt, du giver jo..
14
16 May
PNDORA
I, som er de langsigtede investorer, er de gode. Og de, som er shorter-mafiaen, er de onde. Vi, som ..
14
20 May
PNDORA
Super flot Alf. Gid vi alle (mig selv incl.) ville kunne levere tilsvarende bidrag til dette forum. ..
12

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

22/05/2017 15:26:53
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Man Group PLC : Form 8.3 - [Mariana Resources Limited]

22/05/2017 11:11:42
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Man Group Plc (b) Owner or controller..

HSBC Bank Plc : Form 8.5 (EPT/RI) - Berendsen PLC

22/05/2017 10:57:38
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offe..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Form 8.5 (EPT/RI) - Tesco plc
2
MMCAP International Inc. SPC : Form 8.3 - [Insert name of offeree or offeror]
3
HSBC Bank Plc : Form 8.5 (EPT/RI) - Berendsen Plc
4
Form 8.3 - AXA INVESTMENT MANAGERS : Berendsen PLC
5
MMCAP International Inc. SPC : Form 8.3 - Mariana Resources Limited

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 May 2017 06:00:28
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170517.1 - EUROWEB7 - 2017-05-23 07:00:28 - 2017-05-23 06:00:28 - 1000 - Website: OKAY